Clyra Medical Technologies, a subsidiary of BioLargo, has entered into an exclusive stocking distribution agreement with Advanced Solution, LLC, a national wound‑care logistics provider. The partnership will place ViaCLYR, Clyra’s copper‑iodine complex wound‑irrigation solution, on Advanced Solution’s nationwide network, positioning the product for a U.S. launch in early 2026.
The deal exemplifies BioLargo’s “invent, prove, partner” model. By leveraging Advanced Solution’s established distribution channels, Clyra can accelerate market penetration and generate revenue streams that were previously limited to direct sales. The agreement also expands BioLargo’s commercial footprint beyond its cleantech portfolio, reinforcing the company’s strategy of partnering with specialized distributors to bring innovative products to market.
The wound‑irrigation market is sizable and growing. In 2024 it was valued at $732 million and is projected to reach $1.02 billion by 2034, a CAGR of 3.4%. Rising prevalence of chronic conditions such as diabetes and vascular disease is driving demand for effective, safe irrigation solutions, creating a favorable tailwind for ViaCLYR.
ViaCLYR is built on Clyra’s proprietary Clyrasept™ copper‑iodine complex, which has demonstrated safety, efficacy, biocompatibility, and cost‑effectiveness in FDA‑cleared applications. The technology is effective against a broad spectrum of infection‑causing organisms and has shown efficacy against biofilms, addressing a critical need in wound‑care management.
Steve Harrison, CEO of Clyra, said, “This partnership with Advanced Solution represents a transformative moment for Clyra. Advanced Solution’s proven track record in wound‑care distribution and their commitment to clinical excellence make them the ideal partner to introduce ViaCLYR™ to healthcare providers nationwide.” Dennis P. Calvert, Chairman of Clyra and CEO of BioLargo, added, “We have worked diligently to develop a technology that meets rigorous safety and efficacy standards while addressing real clinical needs.”
BioLargo’s Q2 2025 revenue was $2.777 million, largely driven by sales of its pet‑odor product Pooph. No financial terms were disclosed for the distribution agreement, but the partnership is expected to generate new revenue streams for Clyra and strengthen BioLargo’s overall portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.